---
title: "XTALPI appointed former JP Morgan senior executive Zhou Feiran as Chief Financial Officer"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/278634080.md"
description: "XTALPI announced that Zhou Feiran has been appointed as Chief Financial Officer since yesterday. He has over 12 years of capital markets and investment merger and acquisition experience in the healthcare industry, having served as an Executive Director in JP Morgan's Global Healthcare Investment Banking Division and as a Vice President at Bank of America Merrill Lynch, focusing on financing and merger and acquisition projects in the fields of biotechnology and pharmaceuticals"
datetime: "2026-03-11T00:48:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278634080.md)
  - [en](https://longbridge.com/en/news/278634080.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278634080.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/278634080.md) | [English](https://longbridge.com/en/news/278634080.md)


# XTALPI appointed former JP Morgan senior executive Zhou Feiran as Chief Financial Officer

According to a report from Economic Information Agency on the 11th, XTALPI (02228) announced that Zhou Feiran has been appointed as Chief Financial Officer since yesterday.

The group stated that Zhou Feiran has over 12 years of experience in capital markets and investment mergers and acquisitions in the healthcare industry. He worked at JP Morgan from 2020 to this year, serving as Executive Director of the Global Healthcare Investment Banking Division before leaving; and from 2015 to 2020, he worked at Bank of America Merrill Lynch in the New York and Hong Kong offices, serving as Vice President of the Global Healthcare Investment Banking Division before leaving. During his tenure, he focused on biotechnology, pharmaceuticals, medical devices, and healthcare services, leading numerous benchmark financing, mergers and acquisitions, and business cooperation projects in the industry. (wh)

### 相關股票

- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md)
- [XTALPI (02228.HK)](https://longbridge.com/zh-HK/quote/02228.HK.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md)

## 相關資訊與研究

- [Clover Biopharmaceuticals Details Capped Payment Deal With Gavi, Easing US$224 Million Exposure](https://longbridge.com/zh-HK/news/281511185.md)
- [Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines](https://longbridge.com/zh-HK/news/280923090.md)
- [08:33 ETDrugwatch Investigation Reveals Big Pharma Profits Continue to Outpace Billions in Legal Penalties](https://longbridge.com/zh-HK/news/281368752.md)
- [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/zh-HK/news/281231901.md)
- [Assessing BioArctic (OM:BIOA B) Valuation After New Lecanemab Data And Regulatory Milestones](https://longbridge.com/zh-HK/news/281644038.md)